AGEN is an interesting company deserving of some discussion\investment consideration in my opinion.
Worthwhile article on the company and to the workings of wall street (piper Jaffrey suspended coverage at 12/01 because it didn't get the secondary offering business)
nyba.org
AGEN is not discussed much on SI, and when it is it is just as likely to be mentioned on the biotech short thread as it is to be mentioned favorably. But some of the shorts concerns (CFO leaving and Jaffrey coverage suspension) were explained in the above article. Short ratio is rather high at about 20% of the float (12/03).
TA aficionados would probably wait for it to pull back (currently 11.77) or clear resistance at 12.40 to 13. A cross of the 50 day sma over the 200 day sma concurrent with a break of resistance might provide a good entry point.
stockcharts.com[l,a]dacanyay[pb50!b200!f][vc60][iUc20!Ll14]&pref=G |
